GlassScriptPhysician profile
Rishi Arora
NPI 1134199367
$13,714.68
in general payments reported to CMS, 2019-2025
20 companies · $8,504 in 2025
The $8,504 reported for 2025 was more than what 77% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $567 · 2021: $534 · 2022: $1,455 · 2023: $634 · 2024: $1,271 · 2025: $8,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,813 · Food and Beverage: $4,032 · Travel and Lodging: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,812.50 |
| Food and Beverage | $4,032.34 |
| Travel and Lodging | $563.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,637.98 | 2025 | |
| Medtronic, INC. | $1,590.24 | 2021-2025 | Pulseselect, Cobalt Dr Mri Surescan, Selectsecure |
| Abbott Laboratories | $1,343.62 | 2020-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Ensite |
| Biotronik INC. | $814.57 | 2019-2022 | |
| Biosense Webster, INC. | $684.93 | 2021-2024 | Carto 3 |
| Boston Scientific Corporation | $672.60 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies, Farapulse |
| Altathera Pharmaceuticals LLC | $356.01 | 2022-2025 | Sotalol Hydrochloride |
| Abbvie INC. | $308.93 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $223.36 | 2023-2024 | Xacduro, Giapreza |
| Astrazeneca Pharmaceuticals LP | $196.59 | 2019-2024 | Wainua |
| Atricure, INC. | $189.08 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Genzyme Corporation | $182.51 | 2023 | |
| Cvrx, INC. | $141.81 | 2025 | Barostim Neo System |
| Gilead Sciences, INC. | $98.81 | 2024 | Vemlidy |
| Sanofi-Aventis U.S. LLC | $87.25 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $56.82 | 2019 | |
| Pfizer INC. | $49.57 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.42 | 2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $23.25 | 2022 | |
| Biogen, INC. | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishi Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.